| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
NMDA Receptor
L-Glutamic acid-13C is the stable isotope-labeled form of L-glutamic acid, which is an excitatory amino acid neurotransmitter. L-Glutamic acid functions as an agonist at all subtypes of glutamate receptors, including metabotropic, kainate, NMDA, and AMPA receptors. The ¹³C-labeled version retains the same receptor binding properties and is used as a tracer to study glutamatergic signaling pathways. |
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
The in vitro activity of L-Glutamic acid-13C mirrors that of L-glutamic acid, which is a key excitatory neurotransmitter. It acts as an agonist for various glutamate receptors, including NMDA, AMPA, and kainate receptors. In research settings, the ¹³C-labeled compound is used to trace metabolic pathways and study neurotransmitter function in cell-based assays. |
| ln Vivo |
In vivo, L-Glutamic acid-13C is used as a tracer to study amino acid metabolism and neurotransmitter turnover. By tracking the ¹³C label, researchers can monitor the incorporation of glutamic acid into proteins and other metabolites, as well as its conversion to other neurotransmitters like GABA. This provides valuable insights into metabolic fluxes and neurochemical processes in living organisms.
|
| Enzyme Assay |
Experimental protocols for L-Glutamic acid-13C typically involve its use as a tracer in metabolic flux analysis. The compound is added to cell culture media or administered to animals, and the incorporation of the ¹³C label into various metabolites (e.g., citric acid cycle intermediates, amino acids, and neurotransmitters) is tracked using mass spectrometry or NMR spectroscopy.
|
| Cell Assay |
Cellular assays using L-Glutamic acid-13C involve treating cells with the labeled compound and then analyzing the cell lysates or media by mass spectrometry. This allows researchers to study glutamic acid uptake, metabolism, and its role in cellular pathways. The ¹³C label provides a distinct mass shift that enables precise quantification and tracing of the compound.
|
| Animal Protocol |
In animal studies, L-Glutamic acid-13C is administered to rodents (e.g., via intravenous injection or oral gavage). Blood, cerebrospinal fluid, or tissue samples are collected at various time points and analyzed by mass spectrometry. This allows for the study of glutamic acid pharmacokinetics, brain uptake, and its incorporation into metabolic pathways.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of L-Glutamic acid-13C are similar to those of endogenous L-glutamic acid. It is rapidly metabolized and incorporated into various metabolic pathways. The compound is water-soluble and is typically formulated in saline or other aqueous buffers for administration.
|
| Toxicity/Toxicokinetics |
L-Glutamic acid-13C is a stable, non-radioactive isotope and poses minimal radiological risk. It is intended for research use only and is not for therapeutic or diagnostic use in humans. Standard laboratory safety practices should be followed when handling this compound. Its toxicological profile is expected to be similar to that of L-glutamic acid, which is generally recognized as safe at physiological concentrations.
|
| References |
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
[2]. Giorguieff MF, et al. Presynaptic effect of L-glutamic acid on the release of dopamine in rat striatal slices. Neurosci Lett. 1977 Oct;6(1):73-7. |
| Additional Infomation |
L-Glutamic acid-13C is a stable isotope-labeled compound with an isotopic enrichment of 99 atom % ¹³C. It is supplied as a white crystalline solid. Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process.
|
| Molecular Formula |
C413CH9NO4
|
|---|---|
| Molecular Weight |
148.12
|
| Exact Mass |
148.057
|
| CAS # |
115473-51-3
|
| Related CAS # |
L-Glutamic acid;56-86-0
|
| PubChem CID |
16213454
|
| Appearance |
Typically exists as solid at room temperature
|
| Melting Point |
205ºC (dec.)(lit.)
|
| LogP |
-3.7
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
10
|
| Complexity |
145
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
OC(C[13CH2][C@@H](C(=O)O)N)=O
|
| InChi Key |
WHUUTDBJXJRKMK-AANACRNLSA-N
|
| InChi Code |
InChI=1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1/i1+1
|
| Chemical Name |
(2S)-2-amino(313C)pentanedioic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.7513 mL | 33.7564 mL | 67.5128 mL | |
| 5 mM | 1.3503 mL | 6.7513 mL | 13.5026 mL | |
| 10 mM | 0.6751 mL | 3.3756 mL | 6.7513 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
